Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$51.45 USD
-0.41 (-0.79%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $51.42 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Ionis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 788 | 587 | 810 | 729 | 1,123 |
Cost Of Goods | 9 | 14 | 11 | 12 | 4 |
Gross Profit | 779 | 573 | 800 | 717 | 1,118 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,132 | 983 | 830 | 889 | 752 |
Income After Depreciation & Amortization | -354 | -410 | -30 | -172 | 366 |
Non-Operating Income | 101 | 160 | 10 | 47 | 30 |
Interest Expense | 81 | 8 | 9 | 45 | 49 |
Pretax Income | -334 | -258 | -29 | -170 | 347 |
Income Taxes | 32 | 12 | -1 | 317 | 44 |
Minority Interest | 0 | 0 | 0 | -35 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -366 | -270 | -29 | -487 | 303 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -366 | -270 | -29 | -451 | 303 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -354 | -375 | 12 | -105 | 414 |
Depreciation & Amortization (Cash Flow) | 0 | 35 | 42 | 67 | 48 |
Income After Depreciation & Amortization | -354 | -410 | -30 | -172 | 366 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 143.00 | 142.00 | 141.00 | 140.00 | 143.00 |
Diluted EPS Before Non-Recurring Items | -2.56 | -1.90 | -0.20 | -3.23 | 2.08 |
Diluted Net EPS (GAAP) | -2.56 | -1.90 | -0.20 | -3.23 | 2.08 |
Fiscal Year end for Ionis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 119.50 | 324.50 | 144.21 | 188.41 |
Cost Of Goods | NA | 2.15 | 3.06 | 2.19 | 2.54 |
Gross Profit | NA | 117.35 | 321.44 | 142.02 | 185.87 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 266.86 | 327.57 | 285.28 | 276.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -149.51 | -6.13 | -143.26 | -90.20 |
Non-Operating Income | NA | 28.90 | 25.92 | 24.44 | 32.69 |
Interest Expense | NA | 22.11 | 22.41 | 21.98 | 19.95 |
Pretax Income | NA | -142.73 | -2.77 | -140.81 | -77.45 |
Income Taxes | NA | 0.08 | 6.50 | 6.60 | 7.84 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -142.80 | -9.26 | -147.41 | -85.29 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -142.80 | -9.26 | -147.41 | -85.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 146.00 | 144.00 | 143.00 | 143.00 |
Diluted EPS Before Non-Recurring Items | NA | -0.98 | -0.06 | -1.03 | -0.60 |
Diluted Net EPS (GAAP) | NA | -0.98 | -0.06 | -1.03 | -0.60 |